PCIB PCI Biotech Holding ASA

PCI Biotech: Notice of Annual General Meeting 2020

PCI Biotech: Notice of Annual General Meeting 2020

Oslo, Norway 6 May 2020 - The Annual General Meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 27 May 2020 at 10:00am (CEST).

Due to the extraordinary situation with the Covid-19 pandemic, the Board has found it necessary to urge shareholders to exercise their shareholder rights through advance votes by electronic communication via VPS Investor Services or to vote by proxy prior to the meeting and not attend the Annual General Meeting in person.

The notice including attendance, proxy and advance voting forms will be mailed to all shareholders with known address. The complete notice, including executive remuneration statement and the recommendation from the Nomination Committee, is attached to this notification and will also be available at PCI Biotech's corporate website .

For further information, please contact:

Ronny Skuggedal, CFO, E-mail:

Office: Mobile:

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Attachments

EN
06/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCI Biotech Holding ASA

 PRESS RELEASE

Notice of Extraordinary General Meeting, proposed company dissolution ...

Notice of Extraordinary General Meeting, proposed company dissolution and delisting Oslo, Norway 23 February 2026 – An extraordinary general meeting of PCI Biotech Holding ASA (‘PCI Biotech’ or ‘Company’) will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 16 March 2026 at 10:00am (CET). The proposed resolutions include company dissolution and delisting from Euronext Oslo Børs. The Board of Directors’ proposed resolution to dissolve PCI Biotech is made as there is no longer any operational activity in the Company, nor is it expected that it will resume such acti...

 PRESS RELEASE

PCI Biotech initiates a process to evaluate the opportunity for a stru...

PCI Biotech initiates a process to evaluate the opportunity for a structured wind-up process Oslo (Norway), 29 January 2026 – PCI Biotech (OSE: PCIB) refers to its latest announcement of 8 January 2026 regarding the discontinuation of all R&D operations and the continued exploration of strategic alternatives. This evaluation has now been concluded. Following careful consideration of the PCI Biotech group’s circumstances, the Board has resolved to initiate a process to evaluate the opportunity for a structured wind-up. The liquidity position of the PCI Biotech group remains critical, casti...

 PRESS RELEASE

PCI Biotech announces discontinuation of R&D operations and continues ...

PCI Biotech announces discontinuation of R&D operations and continues evaluation of future options Oslo (Norway), 8 January 2026 – PCI Biotech (OSE: PCIB). Reference is made to the company’s latest announcement dated 23rd October 2025. The external evaluation of a new bioprocessing technology has been concluded, with no prospects for further collaboration. As PCI Biotech’s limited operations were contingent upon sustained external interest, all R&D operations will now be discontinued. In recent months, various strategic alternatives have been explored, and this process continues. The evalu...

 PRESS RELEASE

PCI Biotech update

PCI Biotech update Oslo (Norway), 23 October 2025 – PCI Biotech (OSE: PCIB) today provides an update on the ongoing evaluation of its operations.  Reference is made to the company’s announcements dated 18th August 2025 and 25th September 2025, as well as the interim report for the first half of 2025 published on 29th August 2025. As previously communicated, current activities are focused on the evaluation of a new bioprocessing technology by an undisclosed party, conducted under a material transfer agreement without financial terms. The company’s limited operations and the group’s future...

 PRESS RELEASE

PCI Biotech update on future operations

PCI Biotech update on future operations Oslo (Norway), 25 September 2025 – PCI Biotech (OSE:PCIB) today announces an update on the ongoing evaluation of its future operations. Reference is made to the announcement on 18th August 2025 regarding the discontinuation of further development of the PCL technology. The decision was based on insufficient progress, which extended project timelines and increased resource requirements, elevating the overall project risk to an unacceptable level. Consequently, PCI Biotech decided to discontinue further development. PCI Biotech's immediate priority ha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch